Publication at Faculty of Medicine in Hradec Králové |
2010
Abstract
Myelodysplastic syndrome represent a heterogenous group of clonal hematopoietic disorders. Accurate classification and prediction of survival are essential for selection of optimal therapy.
The WHO classification-based prognostic scoring system permits more useful dynamic estimation of survival and risk of AML transformation in individual patients not only at the time of diagnosis but also throughout the course of their disease.